PegBio’s PB‑119 (Paidakang) Wins NMPA Approval for Type 2 Diabetes Treatment
PegBio Co., Ltd. (HKG: 2565) announced that its next‑generation GLP‑1 receptor agonist PB‑119, marketed under...
PegBio
PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...
Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...
PegBio Files for IPO on Hong Kong Stock Exchange
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...